Our study clearly demonstrated the effects of EGCG on
the mesenteric and retroperitoneal adipose depots. Previously,
weight loss studies in humans showed that visceral adipose tissue
is more metabolically active than subcutaneous adipose tissue,
suggesting the increased risk for metabolic syndrome by adipose
tissue is depot specific (27